HK1049661B - N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]amide inhibitor of cyclin-dependent kinase - Google Patents

N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]amide inhibitor of cyclin-dependent kinase Download PDF

Info

Publication number
HK1049661B
HK1049661B HK03100935.5A HK03100935A HK1049661B HK 1049661 B HK1049661 B HK 1049661B HK 03100935 A HK03100935 A HK 03100935A HK 1049661 B HK1049661 B HK 1049661B
Authority
HK
Hong Kong
Prior art keywords
thio
methyl
oxazolyl
thiazolyl
compound according
Prior art date
Application number
HK03100935.5A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1049661A1 (en
Inventor
N. Misra Raj
Xiao Hai-Yun
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/464,511 external-priority patent/US6262096B1/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HK1049661A1 publication Critical patent/HK1049661A1/en
Publication of HK1049661B publication Critical patent/HK1049661B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK03100935.5A 1999-12-15 2000-12-07 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]amide inhibitor of cyclin-dependent kinase HK1049661B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US464511 1999-12-15
US09/464,511 US6262096B1 (en) 1997-11-12 1999-12-15 Aminothiazole inhibitors of cyclin dependent kinases
US61662700A 2000-07-26 2000-07-26
PCT/US2000/033501 WO2001044242A1 (en) 1999-12-15 2000-12-07 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases

Publications (2)

Publication Number Publication Date
HK1049661A1 HK1049661A1 (en) 2003-05-23
HK1049661B true HK1049661B (en) 2005-10-07

Family

ID=27041008

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03100935.5A HK1049661B (en) 1999-12-15 2000-12-07 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]amide inhibitor of cyclin-dependent kinase

Country Status (29)

Country Link
EP (1) EP1240166B1 (enExample)
JP (1) JP2003516987A (enExample)
KR (1) KR100738132B1 (enExample)
CN (1) CN1433416A (enExample)
AR (1) AR026974A1 (enExample)
AT (1) ATE289306T1 (enExample)
AU (1) AU783719B2 (enExample)
BR (1) BR0016424A (enExample)
CA (1) CA2394552A1 (enExample)
CO (1) CO5261565A1 (enExample)
CZ (1) CZ20022015A3 (enExample)
DE (1) DE60018205T2 (enExample)
DK (1) DK1240166T3 (enExample)
EG (1) EG24168A (enExample)
ES (1) ES2236034T3 (enExample)
HK (1) HK1049661B (enExample)
HU (1) HUP0301032A3 (enExample)
IL (2) IL149755A0 (enExample)
MX (1) MXPA02005870A (enExample)
MY (1) MY125768A (enExample)
NO (1) NO323726B1 (enExample)
NZ (1) NZ519120A (enExample)
PE (1) PE20011026A1 (enExample)
PL (1) PL364921A1 (enExample)
PT (1) PT1240166E (enExample)
RU (1) RU2002119016A (enExample)
TW (1) TWI273103B (enExample)
UY (1) UY26481A1 (enExample)
WO (1) WO2001044242A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
WO2002010162A1 (en) * 2000-07-26 2002-02-07 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6638926B2 (en) 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2432799C (en) 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
PT1532145E (pt) 2002-08-02 2007-01-31 Vertex Pharma Composiçoes de pirazole úteis como inibidores de gsk-3
US7392929B1 (en) 2004-07-26 2008-07-01 Zephyros, Inc. Weldable synthetic material
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
WO2007056163A2 (en) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
US8236128B2 (en) 2006-10-26 2012-08-07 Zephyros, Inc. Adhesive materials, adhesive parts formed therewith and their uses
WO2008063933A2 (en) * 2006-11-10 2008-05-29 Massachusetts Institute Of Technology Pak modulators
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
KR100738132B1 (ko) 2007-07-10
EP1240166B1 (en) 2005-02-16
WO2001044242A1 (en) 2001-06-21
PT1240166E (pt) 2005-07-29
KR20020067546A (ko) 2002-08-22
PE20011026A1 (es) 2001-12-02
BR0016424A (pt) 2002-08-20
ATE289306T1 (de) 2005-03-15
TWI273103B (en) 2007-02-11
CA2394552A1 (en) 2001-06-21
PL364921A1 (en) 2004-12-27
HUP0301032A3 (en) 2009-03-30
EG24168A (en) 2008-09-10
HK1049661A1 (en) 2003-05-23
IL149755A0 (en) 2002-12-01
CO5261565A1 (es) 2003-03-31
WO2001044242A9 (en) 2001-11-08
DE60018205T2 (de) 2006-02-16
NZ519120A (en) 2004-03-26
UY26481A1 (es) 2001-07-31
EP1240166A1 (en) 2002-09-18
CN1433416A (zh) 2003-07-30
DK1240166T3 (da) 2005-06-20
CZ20022015A3 (cs) 2003-02-12
NO20022817L (no) 2002-08-14
NO323726B1 (no) 2007-07-02
HUP0301032A2 (hu) 2003-08-28
ES2236034T3 (es) 2005-07-16
AR026974A1 (es) 2003-03-05
JP2003516987A (ja) 2003-05-20
MY125768A (en) 2006-08-30
AU2726401A (en) 2001-06-25
AU783719B2 (en) 2005-12-01
MXPA02005870A (es) 2003-01-28
RU2002119016A (ru) 2004-01-10
DE60018205D1 (en) 2005-03-24
NO20022817D0 (no) 2002-06-13
IL149755A (en) 2009-09-22

Similar Documents

Publication Publication Date Title
US6515004B1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
EP1240166B1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases
EP1240165B1 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
ZA200204349B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases.
IL153591A (en) History of N–] 5 -))) 5– Alkyl– 2 – Oxazolil (Thio (–2 – thiazolil [carboxamide and pharmaceutical preparations containing them)
LT5106B (lt) Nuo ciklinų priklausomų kinazių n-[5-[[[5-alkil-2-oxazolil]metil]tio]-2-tiazolil]karboksamido inhibitoriai
ZA200300452B (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20101207